I encourage you all to re-read my very comprehensive post comparing the 5-point MACE vs. the 3-point MACE in the SUSTAIN/ASSURE post-hoc analysis. If you read through this, you will appreciate that most of the events that comprised the 5-point MACE were of the less severe variety that are not counted in the 3-point MACE. Read through and you will also appreciate that the event rate in BETonMACE trial design is based upon that of the EXAMINE trial, which is ~10.5% at 18 months. In both EXAMINE and BETonMACE, they are diabetic patients with a recent (7-90 days) acute coronary syndrome event.

So far, only a small number of study sites have been activated according to what we see on Clinicaltrials.gov and the EU clinical trials register. So it's going to be some time before patient recruitment is in full swing. Be realistic about your timelines and expectations, but still be optimistic about the results. I sure am!

Here's the "old" post.

BearDownAZ